Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 3/20 | 0.33 |
| ▸ | RAB9A | P51151 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | LTA4H | P09960 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | GRM5 | P41594 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4235041 | 0.91 | NPC1 (0.33) | NPC1RAB9AMEN1KMT2AATM | |
| SCHEMBL4238823 | 0.90 | — | — | |
| SCHEMBL4238455 | 0.90 | LTA4H (0.35) | NPC1RAB9AMEN1KMT2AATM | |
| SCHEMBL4506959 | 0.89 | NPC1 (0.35) | NPC1RAB9AMEN1KMT2AATM | |
| SCHEMBL5346339 | 0.89 | NPC1 (0.35) | NPC1RAB9AMEN1KMT2AATM | |
| SCHEMBL13854964 | 0.85 | P2RX3 (0.33) | GRM5 | |
| SCHEMBL4237406 | 0.83 | MAPT (0.44) | NPC1RAB9AMEN1KMT2AATM | |
| SCHEMBL4515171 | 0.82 | LTA4H (0.36) | NPC1RAB9AMEN1KMT2AATM | |
| SCHEMBL4228528 | 0.81 | LTA4H (0.32) | NPC1RAB9AMEN1KMT2AATM | |
| SCHEMBL4513365 | 0.80 | NPC1 (0.34) | NPC1RAB9AMEN1KMT2AATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090131420-A1 | Novel Heterocyclic Analogs of Biphenyl Ethers | ORCHID RESEARCH LABORATORIES, LTD. (IN) | 2009-05-21 | — | — | US | claimed |
| WO-2007042878-A1 | NOVEL HETEROCYCLIC ANALOGS OF BIPHENYL ETHERS | ORCHID RESEARCH LABORATORIES LIMITED (IN) | 2007-04-19 | — | — | WO | claimed |
| US-20090131420-A1 | Novel Heterocyclic Analogs of Biphenyl Ethers | ORCHID RESEARCH LABORATORIES, LTD. (IN) | 2009-05-21 | — | — | US | disclosed |
| US-20090131420-A1 | Novel Heterocyclic Analogs of Biphenyl Ethers | ORCHID RESEARCH LABORATORIES, LTD. (IN) | 2009-05-21 | — | — | US | disclosed |
| WO-2007042878-A1 | NOVEL HETEROCYCLIC ANALOGS OF BIPHENYL ETHERS | ORCHID RESEARCH LABORATORIES LIMITED (IN) | 2007-04-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131420-A1 | Novel Heterocyclic Analogs of Biphenyl Ethers | UGT2B7, CYP4B1, CYP1B1 | NPC1 633/4885RAB9A 1148/4885MEN1 932/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.